Is CABA or RANI more profitable?

Rani Therapeutics' return on equity of -104.60% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Rani Therapeutics N/A -104.60% -65.17%

Does the media prefer CABA or RANI?

In the previous week, Cabaletta Bio had 5 more articles in the media than Rani Therapeutics. MarketBeat recorded 7 mentions for Cabaletta Bio and 2 mentions for Rani Therapeutics. Cabaletta Bio's average media sentiment score of 1.08 beat Rani Therapeutics' score of 0.94 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RANI or PRTA?

In the previous week, Rani Therapeutics and Rani Therapeutics both had 2 articles in the media. Rani Therapeutics' average media sentiment score of 0.94 beat Prothena's score of 0.93 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PBYI or RANI?

In the previous week, Puma Biotechnology had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 5 mentions for Puma Biotechnology and 2 mentions for Rani Therapeutics. Puma Biotechnology's average media sentiment score of 1.05 beat Rani Therapeutics' score of 0.94 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, KMDA or RANI?

Kamada has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.52 $20.20M $0.38 20.84 Rani Therapeutics $1.63M 72.06 -$29.67M -$0.27 N/A

Is KMDA or RANI more profitable?

Kamada has a net margin of 11.60% compared to Rani Therapeutics' net margin of 0.00%. Kamada's return on equity of 8.37% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Rani Therapeutics N/A -104.60% -65.17%

Does the media refer more to KMDA or RANI?

In the previous week, Kamada and Kamada both had 2 articles in the media. Rani Therapeutics' average media sentiment score of 0.94 beat Kamada's score of 0.93 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KYTX or RANI more profitable?

Kyverna Therapeutics' return on equity of -81.92% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% Rani Therapeutics N/A -104.60% -65.17%

Does the media refer more to KYTX or RANI?

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Kyverna Therapeutics and 2 mentions for Rani Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat Rani Therapeutics' score of 0.94 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rani Therapeutics (RANI) Competitors

$0.84 +0.02 (+2.51%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.02 (+1.95%)

As of 09/11/2026 07:32 PM Eastern

Compare

RANI vs. CABA, PRTA, PBYI, KMDA, and KYTX

Should you buy Rani Therapeutics stock or one of its competitors? Rani Therapeutics's main competitors and comparable companies include Cabaletta Bio (CABA), Prothena (PRTA), Puma Biotechnology (PBYI), Kamada (KMDA), and Kyverna Therapeutics (KYTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rani Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Cabaletta Bio currently has a consensus price target of $15.33, suggesting a potential upside of 461.66%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 938.45%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Cabaletta Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rani Therapeutics has higher revenue and earnings than Cabaletta Bio. Rani Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Rani Therapeutics	$1.63M	72.06	-$29.67M	-$0.27	N/A

In the previous week, Cabaletta Bio had 5 more articles in the media than Rani Therapeutics. MarketBeat recorded 7 mentions for Cabaletta Bio and 2 mentions for Rani Therapeutics. Cabaletta Bio's average media sentiment score of 1.08 beat Rani Therapeutics' score of 0.94 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cabaletta Bio has a beta of 3.27, indicating that its share price is 227% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Rani Therapeutics' return on equity of -104.60% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Rani Therapeutics	N/A	-104.60%	-65.17%

30.2% of Rani Therapeutics shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Rani Therapeutics beats Cabaletta Bio on 9 of the 13 factors compared between the two stocks.

How does Rani Therapeutics compare to Prothena?

Rani Therapeutics (NASDAQ:RANI) and Prothena (NASDAQ:PRTA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Rani Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Prothena	-80.68%	-16.45%	-14.51%

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rani Therapeutics currently has a consensus target price of $8.75, indicating a potential upside of 938.45%. Prothena has a consensus target price of $24.57, indicating a potential upside of 175.16%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Rani Therapeutics is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Rani Therapeutics and Rani Therapeutics both had 2 articles in the media. Rani Therapeutics' average media sentiment score of 0.94 beat Prothena's score of 0.93 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	72.06	-$29.67M	-$0.27	N/A
Prothena	$9.68M	48.29	-$244.09M	-$0.84	N/A

Rani Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Prothena has a beta of -0.33, meaning that its share price is 133% less volatile than the broader market.

Summary

Rani Therapeutics beats Prothena on 9 of the 14 factors compared between the two stocks.

How does Rani Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Puma Biotechnology had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 5 mentions for Puma Biotechnology and 2 mentions for Rani Therapeutics. Puma Biotechnology's average media sentiment score of 1.05 beat Rani Therapeutics' score of 0.94 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology presently has a consensus target price of $6.00, indicating a potential downside of 34.21%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 938.45%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Puma Biotechnology has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.06	$31.11M	$0.52	17.54
Rani Therapeutics	$1.63M	72.06	-$29.67M	-$0.27	N/A

Puma Biotechnology has a net margin of 11.50% compared to Rani Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Rani Therapeutics	N/A	-104.60%	-65.17%

Puma Biotechnology has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Puma Biotechnology beats Rani Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Kamada?

Kamada (NASDAQ:KMDA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Kamada has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Kamada has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.52	$20.20M	$0.38	20.84
Rani Therapeutics	$1.63M	72.06	-$29.67M	-$0.27	N/A

In the previous week, Kamada and Kamada both had 2 articles in the media. Rani Therapeutics' average media sentiment score of 0.94 beat Kamada's score of 0.93 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20.4% of Kamada shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kamada has a net margin of 11.60% compared to Rani Therapeutics' net margin of 0.00%. Kamada's return on equity of 8.37% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Rani Therapeutics	N/A	-104.60%	-65.17%

Kamada presently has a consensus target price of $13.00, indicating a potential upside of 64.14%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 938.45%. Given Rani Therapeutics' higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Kamada beats Rani Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Kyverna Therapeutics had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Kyverna Therapeutics and 2 mentions for Rani Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat Rani Therapeutics' score of 0.94 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Kyverna Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 313.22%. Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 938.45%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Kyverna Therapeutics' return on equity of -81.92% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
Rani Therapeutics	N/A	-104.60%	-65.17%

Rani Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
Rani Therapeutics	$1.63M	72.06	-$29.67M	-$0.27	N/A

Summary

Rani Therapeutics beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RANI vs. The Competition

Export

Metric	Rani Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$117.45M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	N/A	14.18	274.94	25.36
Price / Sales	72.06	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	2.48	15.12	10.33	6.20
Net Income	-$29.67M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-2.62%	-4.34%	-3.32%	-2.35%
1 Month Performance	5.60%	0.54%	-0.53%	-3.23%
1 Year Performance	68.65%	40.74%	23.51%	8.79%

Rani Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RANI Rani Therapeutics	3.7523 of 5 stars	$0.84 +2.5%	$8.75 +938.5%	+68.7%	$117.45M	$1.63M	N/A	110	Gap Up
CABA Cabaletta Bio	3.2701 of 5 stars	$2.78 +1.3%	$15.33 +452.6%	+48.4%	$470.47M	N/A	N/A	50	News Coverage Analyst Downgrade
PRTA Prothena	3.1151 of 5 stars	$8.94 -0.9%	$24.57 +175.0%	+8.8%	$468.32M	$9.68M	N/A	130	Positive News Analyst Upgrade
PBYI Puma Biotechnology	1.0713 of 5 stars	$8.98 -2.1%	$6.00 -33.2%	+104.0%	$463.29M	$231.24M	17.26	200
KMDA Kamada	4.9359 of 5 stars	$7.92 -0.9%	$13.00 +64.1%	+12.8%	$455.48M	$180.46M	20.84	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RANI) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rani Therapeutics (RANI) Competitors

RANI vs. CABA, PRTA, PBYI, KMDA, and KYTX

How does Rani Therapeutics compare to Cabaletta Bio?

Summary

How does Rani Therapeutics compare to Prothena?

Summary

How does Rani Therapeutics compare to Puma Biotechnology?

Summary

How does Rani Therapeutics compare to Kamada?

Summary

How does Rani Therapeutics compare to Kyverna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rani Therapeutics (RANI) Competitors

RANI vs. CABA, PRTA, PBYI, KMDA, and KYTX

How does Rani Therapeutics compare to Cabaletta Bio?

Do analysts prefer CABA or RANI?

Which has higher earnings & valuation, CABA or RANI?

Does the media prefer CABA or RANI?

Which has more risk and volatility, CABA or RANI?

Is CABA or RANI more profitable?

Do institutionals & insiders have more ownership in CABA or RANI?

Summary

How does Rani Therapeutics compare to Prothena?

Is RANI or PRTA more profitable?

Do insiders and institutionals hold more shares of RANI or PRTA?

Do analysts prefer RANI or PRTA?

Does the media favor RANI or PRTA?

Which has better valuation and earnings, RANI or PRTA?

Which has more volatility & risk, RANI or PRTA?

Summary

How does Rani Therapeutics compare to Puma Biotechnology?

Does the media refer more to PBYI or RANI?

Do analysts prefer PBYI or RANI?

Which has stronger valuation & earnings, PBYI or RANI?

Is PBYI or RANI more profitable?

Which has more risk & volatility, PBYI or RANI?

Do insiders & institutionals believe in PBYI or RANI?

Summary

How does Rani Therapeutics compare to Kamada?

Which has more risk and volatility, KMDA or RANI?

Which has higher earnings & valuation, KMDA or RANI?

Does the media refer more to KMDA or RANI?

Do insiders & institutionals have more ownership in KMDA or RANI?

Is KMDA or RANI more profitable?

Do analysts recommend KMDA or RANI?

Summary

How does Rani Therapeutics compare to Kyverna Therapeutics?

Do institutionals & insiders believe in KYTX or RANI?

Does the media refer more to KYTX or RANI?

Which has more risk and volatility, KYTX or RANI?

Do analysts rate KYTX or RANI?

Is KYTX or RANI more profitable?

Which has preferable valuation & earnings, KYTX or RANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RANI vs. The Competition

Rani Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools